摘要
目的:探讨蛋白质芯片技术对肺气虚证和肺阴虚证的研究意义以及两证的血清IL-1β、IL-8、TNF-α表达水平。方法:将肺气虚证和肺阴虚证患者的血清通过Array-ELISA蛋白芯片平台检测。结果:COPD肺气虚组、COPD肺阴虚组、支气管哮喘肺气虚组、支气管哮喘肺阴虚组的血清IL-1β、IL-8、TNF-α水平明显高于健康组水平,差异有统计学意义(P<0.01);COPD肺气虚组与COPD肺阴虚组、支气管哮喘肺气虚组与支气管哮喘肺阴虚组比较,COPD肺阴虚组和支气管哮喘肺阴虚组的血清IL-1β、IL-8、TNF-α水平相对较高,差异有统计学意义(P<0.05);COPD肺气虚组与支气管哮喘肺气虚组、COPD肺阴虚组与支气管哮喘肺阴虚组比较,血清IL-1β、IL-8、TNF-α水平差异无统计学意义(P>0.05)。COPD肺气虚组、COPD肺阴虚组、支气管哮喘肺气虚组、支气管哮喘肺阴虚组点的灰度值(发光信号值)明显比健康组点的灰度值高;COPD肺阴虚组和支气管哮喘肺阴虚组点的灰度值比COPD肺气虚组和支气管哮喘肺气虚组的高;COPD肺气虚组点的灰度值与支气管哮喘肺气虚组的、COPD肺阴虚组点的灰度值与支气管哮喘肺阴虚组的相近。结论:蛋白质芯片技术用于肺气虚证和肺阴虚证是可行的;肺气虚和肺阴虚证是一种慢性以肺部为主的全身炎症综合症,且肺阴虚较肺气虚有加重趋势。
Objective ： Exploring the protein - microarray technology on Fei - Qi deficiency Syndrome and Fei - Yin deficiency Syndrome, and investigating the expression levels of IL - 113, IL - 8, TNF - ct in the serum. Methods ： Detecting the serum of the patients of Fei - Qi deficiency Syndrome and Fei - Yin deficiency Syndrome through the Array - ELISA of protein - microarray platform. Results ： The expression levels of IL - 113, IL - 8, TNF - ct in the serum of Fei - Qi defi- ciency Syndrome and Fei - Yin deficiency Syndrome in COPD group and Fei - Qi deficiency Syndrome and Fei - Yin defi- ciency Syndrome in bronchial asthma group are significantly higher than the levels of the healthy group（ P 〈 O. 01 ）. The expression levels of Fei - Qi deficiency Syndrome in COPD group are lower than the expression levels of Fei - Yin Defi- ciency Syndrome in COPD group, and also the expression levels of Fei - Qi deficiency Syndrome in bronchial asthma group are lower than the expression levels of Fei - Yin deficiency Syndrome in bronchial asthma group, and the differences are significantly （ P 〈 O. 05）. There are no significantly differences of the expression levels of Fei - Qi deficiency Syndrome between COPD group and bronchial asthma group, and also there are no significantly differences of the expression levels of Fei- Yin deficiency Syndrome between COPD group and bronchial asthma group （ P 〈 O. 05）. The point gray values （light- emitting signal values） of Fei- Qi deficiency Syndrome and Fei -Yin deficiency Syndrome in COPD group and Fei - Qi deficiency Syndrome and Fei - Yin deficiency Syndrome in bronchial asthma group are higher than the point gray values in healthy group. The point gray values of Fei - Yin deficiency Syndrome are higher than the point gray values of Fei - Qi deficiency Syndrome. The point gray values of COPD group are similar with the point gray values of bronchial asthma group in Fei - Qi deficiency Syndrome, and the point gray vMues of COPD group are similar with the point gray values of bronchial asthma group in Fei - Yin deficiency Syndrome. Conclusion ： Protein - microarray technology for in- vetigation of Fei - Qi deficiency Syndrome and Fei - Yin deficiency Syndrome is feasible. Fei - Qi deficiency Syndrome and Fei - Yin deficiency Syndrome is a chronic systemic inflammatory lung mainly syndrome, and Fei - Yin deficiency Syndrome has aggravated the trend to Fei -Qi deficiency Syndrome.
出处
《中华中医药学刊》
CAS
2010年第4期705-707,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(30572387)
关键词
肺气虚证
肺阴虚证
蛋白质芯片
Fei-Qi deficiency syndrome
Fei-Yin deficiency syndrome
protein-microarray
